Take the next step with EndoPredict

Get started with EndoPredict by downloading the provider product overview.

Take the next step with EndoPredict

Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.

EndoPredict® Breast Cancer Prognostic Test

Actionable insights to guide personalized breast cancer treatment

EndoPredict empowers you to confidently determine the necessity and duration of hormone therapy and adjuvant chemotherapy by providing an accurate assessment of recurrence risk across years 0-15, in patients with ER+, HER2–, node-negative (N0), or node-positive (N+) breast cancer.1-3

No other test provides the long-term results and robust benefits of EndoPredict

EndoPredict is a next-generation genomic test that provides three distinct, individualized results to guide confident breast cancer treatment decisions.

EndoPredict provides clarity in the complex decisions around breast cancer treatment by predicting recurrence risk up to 15 years.

  • Combines tumor size, nodal status, and a 12-gene molecular score into the EPclin Risk Score to help determine the optimal use of chemotherapy and endocrine therapy1-6
  • Provides clear binary results for high or low-risk categories with no intermediate that could be left up to interpretation
  • Fast turnaround time of less than 7 days

EndoPredict helps you answer:

1

What is the chance my patient’s cancer will return within 10 years?

2

How will their cancer potentially respond to chemotherapy?

3

Can they safely stop hormone treatment (endocrine therapy) at five years?

Safely avoid unnecessary systemic treatment in lower-risk patients1-4

EndoPredict accurately identifies low-risk patients, enabling many to avoid unnecessary chemotherapy and extended endocrine therapy, ensuring that only those who truly need it receive more aggressive treatment.1-4,7,8

More than 70% of node-negative patients are identified as low-risk by EndoPredict graphic

More than 70% of node-negative patients are identified as low-risk by EndoPredict

Up to 30% of N+ patients are identified as low risk by EndoPredict graphic

Up to 30% of N+ patients are identified as low risk by EndoPredict

Do more for more breast cancer patients with a comprehensive risk and recurrence assessment

For a complete approach to breast cancer risk management and treatment planning, EndoPredict should be combined with MyRisk and Precise Tumor to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.

MyRisk® Hereditary Cancer Test product logo

MyRisk accurately identifies patients at higher genetic risk for breast cancer, enabling more proactive and personalized management strategies. Offering the industry’s lowest rates of BRCA1/2 variants of uncertain significance and a lifetime commitment to variant reclassification, MyRisk allows you to confidently tailor screening plans, assess preventive surgery needs, and identify hereditary cancer syndromes for proactive, personalized management strategies.

Precise Tumor® Molecular Profile Test

Precise Tumor analyzes over 500 genes as well as key biomarkers such as microsatellite instability (MSI), tumor mutational burden (TMB), hormone receptor status (HER2, ER, PR), to identify comprehensive guideline-approved targeted treatment options and clinical trials for advanced solid tumors in breast cancer.4

Myriad Oncology’s portfolio of products delivers:

  • Integrated genetic and tumor genomic insights to personalize care for each breast cancer patient
  • Confident risk and recurrence assessments to inform both preventive and therapeutic decisions
  • Streamlined reporting to prioritize actionable insights at every step of the cancer journey
Image of female physician who orders Myriad Oncology germline tests
Image of the Myriad Oncology EndoPredict test kit

The full EndoPredict report includes

  • 12-gene molecular score
  • Tumor stage
  • Nodal status
  • EPclin score
  • Recurrence score

How to test with EndoPredict

Provider completes the test request form (in the portal or via paper TRF)

Myriad’s laboratory processing staff contacts your pathology partner to directly obtain the tumor sample.

Results are sent to the ordering provider (in the portal or via mail)

What to expect with every EndoPredict test

Actionable

EndoPredict provides a clinically actionable genomic assessment of recurrence risk up to 15 years to determine the necessity and duration of hormone therapy and adjuvant chemotherapy.

Affordable

Transparent pricing for genetic results with financial assistance and other affordability options.

Accurate

Treatment-focused reporting includes actionable summaries with clear information to guide surgical decisions.

EndoPredict resources

References:

  1. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
  2. Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for prediction of risk of distant recurrence after endocrine therapy. Ann Oncol. 2016;27(8):1509-1515.
  3. Sestak I, Buus R, Cuzick J, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018;4(4):545-553.
  4. Constantinidou A, Marcou Y, Toss MS, et al. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin Cancer Res. 2022;28(20):4435-4443.
  5. Dubsky P, Brase JC, Jakesz R, et al; on behalf of Austrian Breast and Colorectal Cancer Study Group. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. Br J Cancer. 2013;109(12):2959-2964.
  6. Filipits M, Sestak I, Buus R, et al. Prediction of distant recurrence using EndoPredict among women with ER+, HER2− node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res. 2019;25(13):3865-3872.
  7. Klein E, Kiechle M, Josipovic A, et al. Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024;207(1):119-127.
  8. Schmitt WD, Jank P, Hoffmann I, et al. Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. Cancer Res. 2023;83(5_Suppl):P2-03-23.
  9. Conroy JM, Pabla S, Glenn ST, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One. 2021;16(12):e0260089.

Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.